Dabigatran Etexilate (DE) was approved by the FDA in 2010 to reduce the risk of stroke and systemic embolism in adults with Non-valvular Atrial Fibrillation (NVAF). Compared with warfarin, a traditional anticoagulant drug, DE exhibits a shorter half-life, improved dose-effect relationship, fewer food and drug interactions, and can be taken orally without monitoring the conventional coagulation index. DE can also prevent or reduce the severity of adverse events, such as attenuated drug efficacy or bleeding. It is convenient for patients to take DE due to low levels of individual variation. We review the pharmacological mechanisms, pharmacokinetics and drug interactions, as well as the application of DE for different clinical populations, and provide clinical guidelines.
Keywords: Dabigatran etexilate, Novel oral anticoagulants, pharmacokinetics, drug interactions, specific populations.
Neurotoxicity of Ecstasy (MDMA): An Overview
Current Pharmaceutical Biotechnology Justification of Increasing the Blood Flow Velocity in the Arteries of the Thyroid Gland in Autoimmune Thyroiditis as a Reflection of Endothelial Changes Due to Inflammatory Status
Current Medical Imaging Cognitive Function and the Ageing Process: The Peculiar Role of Mild Thyroid Failure
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Introduction from the Guest Editor: The Many Facets of Heme Oxygenase
Current Neurovascular Research Endothelin-1 and Angiogenesis in Cancer
Current Vascular Pharmacology Epidemiology of Diabetes Mellitus in the United Arab Emirates
Current Diabetes Reviews Pharmacologic Approach to Heart Failure in Children
Current Cardiology Reviews Atrial Fibrillation – Advances in Drug Therapy
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Diabetes, Oxidative Stress, Nitric Oxide and Mitochondria Function
Current Diabetes Reviews Platelet Activation, Inflammatory Mediators and Hypercholesterolemia
Current Vascular Pharmacology Monitoring Therapeutic Anticoagulation with Low Molecular Weight Heparins: Is it Useful or Misleading?
Cardiovascular & Hematological Agents in Medicinal Chemistry Acknowledgements
Current Cardiology Reviews Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?
Current Pharmaceutical Design Gender-Specific Aspects in Primary and Secondary Prevention of Cardiovascular Disease
Current Pharmaceutical Design Microcirculation in Hypertension: An Update on Clinical Significance and Therapy
Current Vascular Pharmacology Altered Homeostatic Functions in Reactive Astrocytes and Their Potential as a Therapeutic Target After Brain Ischemic Injury
Current Pharmaceutical Design Macrophages: Promising Targets for the Treatment of Atherosclerosis
Current Vascular Pharmacology Fructose Consumption, Lipid Metabolism and the Metabolic Syndrome
Current Nutrition & Food Science Physiologic Tailoring of Treatment in Resistant Hypertension
Current Cardiology Reviews Renin-angiotensin System Blockers and Modulation of Radiation-Induced Brain Injury
Current Drug Targets